European defence company shares fall amid Ukraine peace talk hopes; Novo Nordisk reports Ozempic fails to help with Alzheimer’s – business live
NegativeFinancial Markets
- Shares of Novo Nordisk have significantly declined following the announcement that its Ozempic pill did not slow the progression of Alzheimer’s disease in two major studies. This news comes amid broader economic concerns, including a drop in German business morale as the country struggles to recover from two years of economic contraction.
- The failure of Ozempic in Alzheimer’s trials is a setback for Novo Nordisk, which had hoped to expand the drug's applications beyond weight loss. The disappointing results have raised concerns about the company's future growth prospects and investor confidence.
- This development reflects ongoing challenges in the pharmaceutical industry, particularly in the quest for effective Alzheimer’s treatments. It also highlights the fragile state of the German economy, where companies are losing faith in a swift recovery, complicating efforts by leaders like Chancellor Friedrich Merz to stimulate growth.
— via World Pulse Now AI Editorial System
